Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab + DEP for EBV-associated HLH
NCT05164978Unknown
- Sponsor
- Beijing Friendship Hospital
- Start
- May 2021
- Primary completion
- Jan 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Open-label trial of sintilimab in Epstein-Barr Virus-associated Hemophagocytic Lymphohistiocytosis (EBV-HLH), sponsored by Beijing Friendship Hospital. Primary endpoint: Evaluation of treatment response at 8 weeks. Status: unknown.
02
Drugs
sintilimab
03
Conditions
Epstein-Barr Virus-associated Hemophagocytic Lymphohistiocytosis (EBV-HLH)
Beyond the preview
Go deeper on NCT05164978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05164978.